Insights Into Maintenance Therapy in Acute Myeloid Leukemia (AML)
Perspectives on frontline and maintenance therapy for AML and factors that guide treatment choices
Florida – February 9, 2024
Faculty Chair
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
Southwest – February 24, 2024
Faculty Chair
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Southeast – March 16, 2024
Faculty Chair
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
Central – April 20, 2024
Faculty Chair
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
More Information
- San Diego, CA
- California
More Information
- Seattle, WA
- Idaho, Montana, Northern California, Oregon, Washington, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of AML
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
